Cancers | Free Full-Text | Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
Frontiers | Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice - ScienceDirect
Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications | JACC: Clinical Electrophysiology
The METeoric rise of MET in lung cancer - Friedlaender - 2020 - Cancer - Wiley Online Library
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
Frontiers | Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
Overcoming therapy resistance in EGFR-mutant lung cancer | Nature Cancer
Capmatinib for the treatment of non-small cell lung cancer
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer - touchONCOLOGY
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer - Lingzhi Hong, Jianjun Zhang, John V. Heymach, Xiuning Le, 2021
Frontiers | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Complications following novel therapies for non‐small cell lung cancer - Skribek - 2022 - Journal of Internal Medicine - Wiley Online Library
Safety and Tolerability of c-MET Inhibitors in Cancer. - Abstract - Europe PMC
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. - Abstract - Europe PMC
A New Type of Recyclable: Finding New Uses for Established Drugs｜Tokyo Medical and Dental University, National University Corporation
Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells - Han - 2017 - Molecular Oncology - Wiley Online Library
Mechanisms of Action | Investigational Inhibitors in Lung Cancer
Mechanisms of Action | Investigational Inhibitors in Lung Cancer
Capmatinib | Uses, Brand Names, Mechanism Of Action
Various Protein Kinase Inhibitors as Anticancer Agents | Encyclopedia MDPI
